LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Kodu・Aktsiate loetelu・Coherus Oncology Inc

Coherus Oncology Inc

Suletud

SektorTervishoid

1.95 10.8

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.76

Max

2.1

Põhinäitajad
By Trading Economics
Sissetulek	277M 241M
Müük	1.2M 13M
P/E Sektori keskmine	3.509 49.8
Kasumimarginaal	1,892.046
Töötajad	147
EBITDA	-2M -43M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+300% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	13M 259M
Eelmine avamishind	-8.85
Eelmine sulgemishind	1.95

Uudiste sentiment

By Acuity

50%

175 / 346 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

0.9209 / 1.05 Toetus ja vastupanu

Coherus Oncology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. mai 2026, 22:15 UTC

Omandamised, ülevõtmised, äriostud

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11. mai 2026, 23:46 UTC

Market Talk

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11. mai 2026, 23:44 UTC

Market Talk

Nikkei May Rise on AI Enthusiasm -- Market Talk

11. mai 2026, 23:33 UTC

Market Talk

Gold Rises on Possible Position Adjustments -- Market Talk

11. mai 2026, 22:37 UTC

Market Talk

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11. mai 2026, 22:32 UTC

Tulu

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11. mai 2026, 22:02 UTC

Market Talk

Uudisväärsed sündmused

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11. mai 2026, 21:49 UTC

Tulu

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11. mai 2026, 21:42 UTC

Market Talk

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11. mai 2026, 21:32 UTC

Omandamised, ülevõtmised, äriostud

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11. mai 2026, 21:32 UTC

Omandamised, ülevõtmised, äriostud

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11. mai 2026, 21:32 UTC

Omandamised, ülevõtmised, äriostud

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11. mai 2026, 21:32 UTC

Omandamised, ülevõtmised, äriostud

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11. mai 2026, 21:31 UTC

Omandamised, ülevõtmised, äriostud

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11. mai 2026, 21:23 UTC

Omandamised, ülevõtmised, äriostud

CSG Systems Sale to NEC Gets CFIUS Clearance

11. mai 2026, 21:12 UTC

Tulu

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11. mai 2026, 21:12 UTC

Tulu

Ovintiv 1Q Loss/Shr $2.35 >OVV

11. mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

11. mai 2026, 20:44 UTC

Tulu

Steris: Board Approves New $1B Shr Repurchase Program >STE

11. mai 2026, 20:43 UTC

Tulu

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11. mai 2026, 20:32 UTC

Tulu

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11. mai 2026, 20:32 UTC

Tulu

CleanSpark 2Q Rev $136.4M >CLSK

11. mai 2026, 20:30 UTC

Tulu

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11. mai 2026, 20:30 UTC

Tulu

Steris 4Q Cont Ops EPS $2.24 >STE

11. mai 2026, 20:30 UTC

Tulu

Steris 4Q Rev $1.6B >STE

11. mai 2026, 20:30 UTC

Tulu

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11. mai 2026, 20:30 UTC

Tulu

Steris 4Q Adj EPS $2.83 >STE

11. mai 2026, 20:22 UTC

Kuumad aktsiad

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11. mai 2026, 19:37 UTC

Tulu

More Bad News at KKR's Private Credit Fund -- Barrons.com

11. mai 2026, 19:32 UTC

Market Talk

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Coherus Oncology Inc Prognoos

Hinnasiht

By TipRanks

300% tõus

12 kuu keskmine prognoos

Keskmine 7 USD 300%

Kõrge 10 USD

Madal 4 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Coherus Oncology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Coherus Oncology Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9209 / 1.05Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

175 / 346 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.